Tuesday, 11 August 2020


Novartis eye care firm gets EU nod for Jetrea

18 March 2013 | Regulatory | By BioSpectrum Bureau

Novartis eye care firm gets EU nod for Jetrea

Novartis eye care firm gets EU nod for Jetrea

Singapore: Alcon, the global leader in eye care and a division of Novartis, has received European Commission's approval for Jetrea intravitreal injection (ocriplasmin) in the EU for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.

"The approval of Jetrea by the European Commission is a major breakthrough for people with VMT and eye care professionals who, until now, have only had surgical options available to treat this debilitating eye disease. Now they can intervene early with a one-time injection of Jetrea," said Mr Stuart Raetzman, area president, Europe, Middle East and Africa, Alcon.

"Jetrea meets a genuine unmet patient need and demonstrates Alcon's commitment to bringing innovative eye care treatments to people in Europe and throughout the world," he added.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account




Podcast

 

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls